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Vitamin D receptor: Mechanisms for vitamin D resistance in CURRENT MODEL OF 1,25(OH)2D3–VDR ACTION
renal failure. 1,25-dihydroxyvitamin D [1,25(OH)2D3], the hor- The 1,25(OH)2D3 synthesized in the kidney by mito-monal form of vitamin D, controls serum levels of parathyroid
chondrial 1-hydroxylase is transported in the blood byhormone (PTH) and parathyroid hyperplasia. Both 1,25(OH)2D3
actions involve regulation of gene transcription by the carrier proteins. Although vitamin D binding-protein
1,25(OH)2D3/vitamin D receptor (VDR) complex. In advanced (DBP) is the main carrier, 1,25(OH)2D3 also binds albu-
renal failure, in addition to low serum 1,25(OH)2D3 and re- min and lipoproteins [2]. Recently, reports showing thatduced parathyroid vitamin D receptor content, several mecha-
the free form of 1,25(OH)2D3 triggers biological responsesnisms downstream from 1,25(OH)2D3/VDR complex formation
contribute to the impairment of 1,25(OH)2D3 action, including after entering target cells by simple diffusion have been
reduced levels of the retinoid X receptor, RXR, with the conse- challenged by the demonstration that, in renal proximal
quent reduction in VDR/RXR heterodimer formation, and tubular cells, 25-hydroxyvitamin D uptake occurs throughaccumulation of uremic toxins and increases in nuclear levels
receptor (megalin)-mediated endocytosis of the 25(OH)Dof calreticulin, two processes that impair the binding of the
VDR/RXR complex to vitamin D responsive elements in vita- bound to plasma DBP [3]. A similar endocytosis could
min D-regulated genes. VDR/RXR-heterodimer formation mediate the cellular uptake of 1,25(OH)2D3 bound to
and its binding to DNA is critical for 1,25(OH)2D3 regulation DBP or lipoproteins. Uremia-induced reduction in meg-of gene transcription. Early interventions with 1,25(OH)2D3
alin expression may constitute a mechanism for vitamincould delay the onset of vitamin D resistance by preventing both
D resistance independent of abnormalities in VDR con-1,25(OH)2D3 deficiency and its critical consequence, reduction
in VDR content. Once established, vitamin D resistance could tent or function. Once inside the cell, 1,25(OH)2D3 can
be counteracted by vitamin D analogs. While their less calcemic be inactivated by mitochondrial 24-hydroxylase or it can
properties make higher dosing safer, their specificity to recruit
bind the VDR. Ligand binding activates the VDR toco-activator molecules to the transcriptional pre-initiation
translocate from the cytosol to the nucleus, where itcomplex could compensate for reduced 1,25(OH)2D3/VDR by
potentiating VDR-transactivation/transrepression of genes heterodimerizes with its partner, the retinoid X receptor,
critical for normal PTH synthesis and parathyroid cell growth. RXR. The VDR/RXR complex binds specific sequences
in the promoter region of target genes, called vitamin D
response elements (VDRE), and recruits basal transcrip-
Secondary hyperparathyroidism (HPT) is a frequent tion factors and co-regulator molecules to either increase
complication in chronic renal failure characterized by or suppress the rate of gene transcription by RNA-poly-
parathyroid hyperplasia and enhanced synthesis and se- merase II. Numerous genes, transcriptionally induced or
cretion of PTH. 1,25(OH)2D3 is critical in controlling suppressed by the 1,25D/VDR complex, are relevant for
PTH synthesis and parathyroid cell proliferation [1]. the efficacy of 1,25(OH)2D3 therapy in renal failure. The
Similar to most 1,25(OH)2D3 biological responses, its biological actions resulting from vitamin D-regulation of
actions in the parathyroid glands demand a functional their expression include: (a) the classic vitamin D control
vitamin D receptor (VDR). This review presents our
of calcium homeostasis in bone, intestine, and the kidney;
current understanding of the molecular mechanisms that
(b) regulation of the rates of 1,25(OH)2D3 synthesis andcause vitamin D resistance in renal failure and insights
catabolism; (c) suppression of PTH synthesis; (d) modu-into potential new avenues for therapy.
lation of immune responses; and (e) suppression of cell
proliferation [2]. Several mechanisms have been identi-
fied as being responsible for the reduced efficacy of vita-Key words: calcitriol, gene transcription, hyperparathyroidism, hyper-
plasia. min D in controlling the expression of these genes in
renal failure. 2003 by the International Society of Nephrology
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content, abnormalities in steps downstream from ligand
binding to the VDR were demonstrated by the studies
shown in Figure 2, which compares 1,25(OH)2D3 action
in peripheral blood monocytes from normal individuals
and hemodialysis patients. In the presence of a similar
VDR content, the binding of endogenous VDR/RXR
complex to DNA is markedly impaired in uremia, lead-
ing to an 80% inhibition of the ability of exogenous
1,25(OH)2D3 to induce 24-hydroxylase gene transcrip-
tion. Other factors contribute to impairing 1,25(OH)2D3/
VDR control of gene transcription.
Reduced RXR
Studies in unilaterally nephrectomized rats demon-Fig. 1. 1,25(OH)2D3 regulation of gene transcription. 1,25(OH)2D3
strated a reduction in the content of a 50 kD RXR iso-binding activates the VDR to interact with nuclear RXR, basal tran-
scription factors, and co-regulator molecules to activate p21 or repress form in cell extracts from the remnant kidney. This de-
PTH gene transcription by RNA polymerase II. B is basal transcription crease in RXR results in a reduction of the binding offactor.
the endogenous VDR/RXR heterodimer to the VDRE
of the mouse osteopontin promoter. A similar reduction
of RXR content in the parathyroid glands in these rats
could explain their enhanced serum PTH levels in theMECHANISMS FOR IMPAIRED 1,25(OH)2D3/VDR
absence of hypocalcemia or hyperphosphatemia [7].ACTION IN RENAL FAILURE
It can be easily inferred from the diagram depicting Accumulation of uremic toxins
1,25(OH)2D3/VDR control of gene transcription (Fig. 1)
Ultrafiltrate from uremic plasma causes a dose-depen-that, in the parathyroid glands, the magnitude of
dent inhibition of VDR/RXR binding to VDRE and1,25(OH)2D3/VDR inhibition of PTH synthesis and/or
1,25(OH)2D3/VDR-transactivating function [8].parathyroid growth arrest (induction of p21) is deter-
mined mainly by the intracellular levels of both Increases in parathyroid calreticulin
1,25(OH)2D3 and the VDR. It is well known that in renal Calreticulin is a cytosolic protein that binds integrinsfailure, serum 1,25(OH)2D3 decreases with the progres- in the plasma membrane and the DNA-binding domainsive reduction in glomerular filtration rates as renal func-
of nuclear receptors, including the VDR, thus interferingtion deteriorates. In addition to low serum 1,25(OH)2D3, with receptor mediated transactivation. Hypocalcemia,the immunohistochemical study by Fukuda et al [4] of
commonly present in renal failure and caused by both
nodular and diffuse hyperplastic human parathyroid
low 1,25(OH)2D3 or hyperphosphatemia, enhances nu-glands demonstrate a marked reduction in VDR content, clear levels of parathyroid calreticulin. In vitro studies
particularly in areas of more aggressive nodular growth. demonstrate that increases in calreticulin inhibit VDR/
One reason for reduced VDR levels is the low serum RXR binding to VDRE in a dose-dependent manner
1,25(OH)2D3 since the sterol increases VDR mRNA lev- and totally abolish 1,25(OH)2D3 suppression of PTH
els and protein stability, the latter by preventing VDR gene transcription [9].
degradation by the proteasome complex, thus prolonging
the half life of 1,25(OH)2D3-bound VDR over that of Activation of VDR-unrelated pathways interfering
the apo-VDR (unbound receptor) [5]. The actual contri- with 1,25(OH)2D3 signaling
bution of 1,25(OH)2D3 levels to VDR content in vivo In human monocytes and macrophages, cytokine acti-
was demonstrated in uremic rats by a strong correlation vation markedly inhibits 1,25(OH)2D3-VDR gene tran-
between serum 1,25(OH)2D3 and parathyroid VDR con- scription. Activation by the cytokine gamma interferon
tent [6]. This suggests a potential for 1,25(OH)2D3 ther- of its signaling molecule, Stat1, induces physical interac-
apy to correct the reduced parathyroid VDR content in tions between Stat1 and the DNA binding domain of
renal failure patients. In fact, the reduced VDR content the VDR, thus impairing VDR/RXR binding to VDRE
in the parathyroid glands of uremic rats could be in- and gene transcription [10]. The higher levels of inflam-
creased to the levels in normal animals by administration matory cytokines following hemodialysis could contrib-
of either 1,25(OH)2D3 or its analog, 22-oxa-calcitriol [6]. ute to vitamin D resistance.
In addition to impaired formation of the 1,25(OH)2D3/ Little is known at present about how renal failure
VDR complex resulting from the combination of de- affects the last and most critical step in 1,25(OH)2D3/
VDR-mediated transactivation or transrepression. Bind-creases in 1,25(OH)2D3 synthesis and parathyroid VDR
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Fig. 2. Vitamin D resistance unrelated to re-
duced VDR. In spite of similar VDR content
(left panel), endogenous VDR/RXR binding
to human 24-hydroxylase VDRE is markedly
impaired in monocytes from hemodialysis pa-
tients compared to normal volunteers (middle
panel), thus resulting in almost complete inhi-
bition of the ability of exogenous 1,25(OH)2D3
to induce 24-hydroxylase gene transcription
(right panel). U is hemodialysis patients.
initiate transcription (Fig. 3, bottom panel). The complex
interactions of the VDR/RXR with VDRE and co-regu-
lators in VDR transactivation or transrepression of vita-
min D responsive genes suggests that, in uremia, vitamin
D resistance may also result from a decreased expression
of essential coactivator or corepressor molecules or from
defective recruitment of these molecules by the VDR.
Uremia-induced activation of VDR-unrelated signaling
pathways could also interfere the recruitment of coregu-
lator molecules to the VDR transcriptional pre-initiation
complex.
In view of the numerous inhibitory interactions trig-
gered by uremia, what are the mechanisms responsible
for the efficacy of therapy with vitamin D or its less cal-
cemic analogs? Studies by Takeyama et al [14] demon-
strate that the ligand bound to the VDR dictates which
coactivator is recruited by the VDR. This selective re-
cruitment of coactivators has double implications for ther-
apy. If a target cell expresses the coactivators required
by either 1,25(OH)2D3 or its analog, both vitamin D
metabolites will elicit a similar efficacy. However, if the
coactivator required by the analog is limiting or absentFig. 3. Coregulator molecules in 1,25(OH)2D3/VDR regulation of gene
in a target tissue, the analog will elicit a weaker potencytranscription. 1,25(OH)2D3/VDR recruitment of coactivator (top)
and/or corepressor (bottom) molecules to the pre-initiation complex than the parent hormone. This mechanism could cer-
modulates chromatin remodeling and gene transcription. tainly contribute to analog selectivity. Furthermore, ana-
log recruitment to the VDR transcription initiation com-
plex of a coactivator more potent than that recruited by
1,25(OH)2D3 could result in higher potency of the analoging of the VDR/RXR heterodimer to the VDRE of genes
in eliciting a biological response. In fact, preliminaryinduced by vitamin D (Fig. 3, top panel) begins the re-
studies (abstract; Takeyama et al, J Bone Min Res 16:cruitment of coactivator molecules, which act synergisti-
S433, 2001) [14] demonstrated that analog specific re-cally with the VDR to markedly amplify 1,25(OH)2D3
cruitment of corepressor molecules mediate their differ-transactivation [11–13]. These coactivators possess his-
ential transrepression potency of the human PTH gene.tone acetyl transferase activity (SRC-1 and CBP/p300),
Extensive research is mandatory before extrapolatingwhich unfold and expose the DNA. The recruitment
these findings in vitro to VDR transcriptional potencyof a second complement of transcriptional coactivators,
in the parathyroid glands in vivo.including DRIP205 and TRIP, favors the assembly of
In summary, early therapeutic interventions withthe pre-initiation complex and potentiates 1,25D/VDR
1,25(OH)2D3 or its analogs in renal failure result not onlyinduction of transcription. In transcriptional repression,
in prevention of 1,25(OH)2D3 deficiency, but also in thethe VDR/RXR complex bound to negative VDRE, that
reduction in cellular VDR content, thus improving for-is, of genes that are suppressed by vitamin D, recruits
mation of the 1,25D-VDR complex. Adequate preven-co-repressors of the family of HDAC2, thus preventing
DNA exposure and binding of TATA binding protein to tion of hypocalcemia, hyperphosphatemia, and the accu-
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